Edwards Lifesciences Reports Second Quarter Results

Go back to Edwards Lifesciences Reports Second Quarter Results

Edwards Lifesciences (EW) PT Raised to $120 at Oppenheimer

July 30, 2021 6:27 AM EDT

Oppenheimer analyst Suraj Kalia raised the price target on Edwards Lifesciences (NYSE: EW) to $120.00 (from $97.00) while maintaining an Outperform rating.

The analyst commented, "Edwards reported 2Q21 revenues of $1.38B vs. our/consensus' $1.29B/$1.28B estimates and guidance of $1.251.33B. TAVR revenues... More

Edwards Lifesciences (EW) Tops Q2 EPS by 9c; Raises Outlook

July 29, 2021 4:20 PM EDT

Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.64, $0.09 better than the analyst estimate of $0.55. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.28 billion.

GUIDANCE:

Edwards Lifesciences sees FY2021 EPS of $2.07-$2.27, versus the consensus of $2.21.... More